3
Announcements
Trials
Browse
Landscape
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
7
Observational
1
Sponsor
Cancer Type
Thoracic
1
Plasma cell
1
Other hematologic neoplasm
1
Myeloid
1
Lymphoid
1
Genitourinary
1
Gastrointestinal
1
Classical hematology
1
Breast
1
Conditions
Neoplasms
2
Venous Thrombosis
1
Venous Thromboembolism
1
Vascular Diseases
1
Urogenital Neoplasms
1
Thromboembolism
1
Pulmonary Embolism
1
Prostatic Neoplasms
1
Myeloproliferative Disorders
1
Multiple Myeloma
1
Lymphoproliferative Disorders
1
Lymphoma
1
Lymphatic Diseases
1
Lung Neoplasms
1
Leukemia
1
Intestinal Neoplasms
1
Hemostatic Disorders
1
Digestive System Neoplasms
1
Colorectal Neoplasms
1
Breast Neoplasms
1
Interventions
Rivaroxaban
5
apixaban
4
Heparin, Low-Molecular-Weight
2
Dabigatran
2
ribociclib
1
palbociclib
1
edoxaban
1
calcium heparin
1
abemaciclib
1
Tinzaparin
1
Surveys and Questionnaires
1
Observation
1
Nadroparin
1
Mass Screening
1
Heparin
1
Fondaparinux
1
Enoxaparin
1
Data Collection
1
Dalteparin
1
Anticoagulants
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Observational
×
Venous Thromboembolism
×
Tinzaparin
×
Clear all
NCT03099031
2019-12-16
PREDICARE
LEO Pharma
Completed
420 enrolled